Mankind Pharma, one of the largest pharmaceutical manufacturing companies headquartered in India has collaborated with Accenture to hasten its digital renovation expedition to become an intellectual endeavor, civilizing business quickness, performance, and operational effectiveness. Accenture has redesigned the pharma major’s business processes transversely key functions such as investment, provide string, sales, and procurement for enhanced catalog optimization, demand planning, workforce productivity, and product availability.

As part of the project, Accenture deployed a digital platform based on SAP S/4HANA®, a Microsoft Azure cloud-based data lake and Tableau dashboards, as long as cloud-based analytics to help Mankind Pharma get deeper insights into its comprehensive business operations and performance. The policy integrates data in real-time commencing multiple sources across the supply chain, workforce, and sales to provide a consolidated view of market insights. This can help the management team make knowledgeable decisions in the region of the business plan, preparation, and product development. The project was concluded tenuously during the ongoing pandemic with no impact on business continuity.

Arjun Juneja, chief operating officer, Mankind Pharma, states, “At Mankind Pharma, we are committed to product innovation so we can provide high quality and affordable pharmaceutical products to people across the world.”

Rishabh Bindlish, India Life Sciences and global generics lead, Accenture, states, “Digitally transforming our business processes with support from Accenture has been key to unlocking value trapped within the organization, accelerating real-time decision making and improving our product innovation lifecycle. Digital reinvention can not only help pharma companies deliver high-quality and hyper-personalized services, but also improve business performance and build resilience against future disruptions. We are focused on helping Mankind Pharma embrace change and emerge as a data-driven enterprise to enhance its customer-centricity bringing innovative offerings to market at a faster pace and scale for patients.”